These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20517885)

  • 1. Peptidomic profiling of human cerebrospinal fluid identifies YPRPIHPA as a novel substrate for prolylcarboxypeptidase.
    Zhao X; Southwick K; Cardasis HL; Du Y; Lassman ME; Xie D; El-Sherbeini M; Geissler WM; Pryor KD; Verras A; Garcia-Calvo M; Shen DM; Yates NA; Pinto S; Hendrickon RC
    Proteomics; 2010 Aug; 10(15):2882-6. PubMed ID: 20517885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase.
    Soisson SM; Patel SB; Abeywickrema PD; Byrne NJ; Diehl RE; Hall DL; Ford RE; Reid JC; Rickert KW; Shipman JM; Sharma S; Lumb KJ
    BMC Struct Biol; 2010 Jun; 10():16. PubMed ID: 20540760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of prolylcarboxypeptidase (PrCP) inhibitors to validate PrCP as a potential target for obesity.
    Zhou C; Garcia-Calvo M; Pinto S; Lombardo M; Feng Z; Bender K; Pryor KD; Bhatt UR; Chabin RM; Geissler WM; Shen Z; Tong X; Zhang Z; Wong KK; Roy RS; Chapman KT; Yang L; Xiong Y
    J Med Chem; 2010 Oct; 53(19):7251-63. PubMed ID: 20857914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended cleavage specificity of mMCP-1, the major mucosal mast cell protease in mouse-high specificity indicates high substrate selectivity.
    Andersson MK; Pemberton AD; Miller HR; Hellman L
    Mol Immunol; 2008 May; 45(9):2548-58. PubMed ID: 18313755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Enzymatic synthesis of peptides of arginine-chromophore substrates of metalloproteinases and carboxypeptidases].
    Iusupova MP; Kotlova EK; Timokhina EA; Stepanov VM
    Bioorg Khim; 1995 Jan; 21(1):33-8. PubMed ID: 7710422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a specific prolylcarboxypeptidase activity assay and its suitability for plasma and serum measurements.
    Kehoe K; Verkerk R; Sim Y; Waumans Y; Van der Veken P; Lambeir AM; De Meester I
    Anal Biochem; 2013 Dec; 443(2):232-9. PubMed ID: 24036038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation.
    Hooley E; McEwan PA; Emsley J
    J Thromb Haemost; 2007 Dec; 5(12):2461-6. PubMed ID: 17922805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-ray structure determination of human profilin II: A comparative structural analysis of human profilins.
    Nodelman IM; Bowman GD; Lindberg U; Schutt CE
    J Mol Biol; 1999 Dec; 294(5):1271-85. PubMed ID: 10600384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the hydrolytic properties of (serine) carboxypeptidase Y.
    Stennicke HR; Mortensen UH; Breddam K
    Biochemistry; 1996 Jun; 35(22):7131-41. PubMed ID: 8679540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of in vitro peptide substrates for human rhinovirus-14 2A protease.
    Wang QM; Johnson RB; Sommergruber W; Shepherd TA
    Arch Biochem Biophys; 1998 Aug; 356(1):12-8. PubMed ID: 9681985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein.
    Corradin S; Ransijn A; Corradin G; Bouvier J; Delgado MB; Fernandez-Carneado J; Mottram JC; Vergères G; Mauël J
    Biochem J; 2002 Nov; 367(Pt 3):761-9. PubMed ID: 12137567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping.
    Landro JA; Raybuck SA; Luong YP; O'Malley ET; Harbeson SL; Morgenstern KA; Rao G; Livingston DJ
    Biochemistry; 1997 Aug; 36(31):9340-8. PubMed ID: 9235976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human cytomegalovirus protease with a C-terminal (His)6 extension: purification, autocatalytic release of the mature enzyme, and biochemical characterization.
    Tomasselli AG; Paddock DJ; Curry KA; Garlick RL; Leone JW; Lull JM; Mutchler VT; Baker CA; Cavey GS; Mathews WR; Shelly JA; Finzel BC; Baldwin ET; Wells PA; Tomich CS
    Protein Expr Purif; 1998 Dec; 14(3):343-52. PubMed ID: 9882568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity.
    Baechle D; Cansier A; Fischer R; Brandenburg J; Burster T; Driessen C; Kalbacher H
    J Pept Sci; 2005 Mar; 11(3):166-74. PubMed ID: 15635643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly selective hydrolysis of kinins by recombinant prolylcarboxypeptidase.
    Chajkowski SM; Mallela J; Watson DE; Wang J; McCurdy CR; Rimoldi JM; Shariat-Madar Z
    Biochem Biophys Res Commun; 2011 Feb; 405(3):338-43. PubMed ID: 21167814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolylcarboxypeptidase (PrCP) inhibitors and the therapeutic uses thereof: a patent review.
    Graham TH
    Expert Opin Ther Pat; 2017 Oct; 27(10):1077-1088. PubMed ID: 28699813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolylcarboxypeptidase independently activates plasma prekallikrein (fletcher factor).
    Wang J; Matafonov A; Madkhali H; Mahdi F; Watson D; Schmaier AH; Gailani D; Shariat-Madar Z
    Curr Mol Med; 2014; 14(9):1173-85. PubMed ID: 25324000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of a novel inhibitor (UM8190) of prolylcarboxypeptidase (PRCP) on appetite and thrombosis.
    Rabey FM; Gadepalli RS; Diano S; Cheng Q; Tabrizian T; Gailani D; Rimoldi JM; Shariat-Madar Z
    Curr Med Chem; 2012; 19(24):4194-206. PubMed ID: 22664251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of orally active cyclohexane-based prolylcarboxypeptidase (PrCP) inhibitors.
    Debenham JS; Graham TH; Verras A; Zhang Y; Clements MJ; Kuethe JT; Madsen-Duggan C; Liu W; Bhatt UR; Chen D; Chen Q; Garcia-Calvo M; Geissler WM; He H; Li X; Lisnock J; Shen Z; Tong X; Tung EC; Wiltsie J; Xu S; Hale JJ; Pinto S; Shen DM
    Bioorg Med Chem Lett; 2013 Dec; 23(23):6228-33. PubMed ID: 24157366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolylcarboxypeptidase: a cardioprotective enzyme.
    Mallela J; Yang J; Shariat-Madar Z
    Int J Biochem Cell Biol; 2009 Mar; 41(3):477-81. PubMed ID: 18396440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.